Systematic Review of Atypical Hemolytic Uremic Syndrome Biomarkers

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2022 Feb 4

PMID 35118546

Authors

Rupesh Raina

Sidharth K Sethi

Marie-Agnes Dragon-Durey

Amrit Khooblall

Divya Sharma

Priyanka Khandelwal

Ron Shapiro

Olivia Boyer

Hui Kim Yap

Arvind Bagga

Christoph Licht

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Observing biomarkers that affect alternative pathway dysregulation components may be effective in obtaining a new and more rapid diagnostic portrayal of atypical hemolytic uremic syndrome. We have conducted a systematic review on the aHUS biomarkers: C3, C5a, C5b-9, factor B, complement factor B, H, and I, CH50, AH50, D-dimer, as well as anti-CFH antibodies.

Methods: An exhaustive literature search was conducted for aHUS patient population plasma/serum, collected/reported at the onset of diagnosis. A total of 60 studies were included with the data on 837 aHUS subjects, with at least one biomarker reported.

Results: The biomarkers C3 [mean (SD): 72.1 (35.0), median: 70.5 vs. reference range: 75-175 mg/dl, n = 752]; CH50 [28.3 (32.1), 24.3 vs. 30-75 U/ml, n = 63]; AH50 [27.6% (30.2%), 10% vs. ≥ 46%, n = 23]; and CFB [13.1 (6.6), 12.4, vs. 15.2-42.3 mg/dl, n = 19] were lower among aHUS subjects as compared with the reference range. The biomarkers including C4 [mean (SD): 20.4 (9.5), median: 20.5 vs. reference range: 14-40 mg/dl, n = 343]; C4d [7.2 (6.5), 4.8 vs. ≤ 9.8 μg/ml, n = 108]; CFH [40.2 (132.3), 24.5 vs. 23.6-43.1 mg/dl, n = 123 subjects]; and CFI [8.05 (5.01), 6.55 mg/dl vs. 4.4-18.1 mg/dl, n = 38] were all observed to be within the reference range among aHUS subjects. The biomarkers C5a [mean (SD): 54.9 (32.9), median: 48.8 vs. reference range: 10.6-26.3 mg/dl, n = 117]; C5b-9 [466.0 (401.4), 317 (186-569.7) vs. ≤ 250 ng/ml, n = 174]; Bb [2.6 (2.1), 1.9 vs. ≤ 1.6 μg/ml, n = 77] and D-dimer [246 (65.05), 246 vs. < 2.2 ng/ml, 2, n = 2 subjects] were higher among patients with aHUS compared with the reference range.

Conclusion: If a comprehensive complement profile were built using our data, aHUS would be identified by low levels of C3, CH50, AH50, and CFB along with increased levels of C5a, C5b-9, Bb, anti-CFH autoantibodies, and D-dimer. A higher resolution version of the Graphical abstract is available as Supplementary information.

Citing Articles

Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.

Doshi K, Yusuf A, Licht C, Boyer O, Nester C, Murra A Pediatr Res. 2024; .

PMID: 39676096 DOI: 10.1038/s41390-024-03771-7.

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.

Java A Hematology Am Soc Hematol Educ Program. 2024; 2024(1):200-205.

PMID: 39644051 PMC: 11665500. DOI: 10.1182/hematology.2024000543.

Inborn errors of immunity with kidney and urinary tract disorders: a review.

Shajari A, Zare Ahmadabadi A, Ashrafi M, Mahdavi T, Mirzaee M, Mohkam M Int Urol Nephrol. 2024; 56(6):1965-1972.

PMID: 38198013 PMC: 11090940. DOI: 10.1007/s11255-023-03907-4.

Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults.

Avila A, Cao M, Espinosa M, Manrique J, Morales E Front Med (Lausanne). 2023; 10:1264310.

PMID: 38105887 PMC: 10722909. DOI: 10.3389/fmed.2023.1264310.

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.

Cammett T, Garlo K, Millman E, Rice K, Toste C, Faas S Mol Diagn Ther. 2022; 27(1):61-74.

PMID: 36329366 DOI: 10.1007/s40291-022-00620-3.

References

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S . Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5(10):1844-59. PMC: 2974386. DOI: 10.2215/CJN.02210310. View

Yoshida Y, Kato H, Ikeda Y, Nangaku M . Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb. 2018; 26(2):99-110. PMC: 6365154. DOI: 10.5551/jat.RV17026. View

Moake J . Thrombotic microangiopathies. N Engl J Med. 2002; 347(8):589-600. DOI: 10.1056/NEJMra020528. View

Oh J, Oh D, Lee S, Kim J, Kim N, Chong S . Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res. 2019; 54(3):218-228. PMC: 6779945. DOI: 10.5045/br.2019.54.3.218. View

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R . Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016; 20(4):536-543. DOI: 10.1007/s10157-016-1276-6. View

Cataland S, Holers V, Geyer S, Yang S, Wu H . Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014; 123(24):3733-8. DOI: 10.1182/blood-2013-12-547067. View

Nguyen M, Mathew J, Denunzio T, Carmichael M . Diagnosis of atypical hemolytic uremic syndrome and response to eculizumab therapy. Hawaii J Med Public Health. 2014; 73(9 Suppl 1):22-4. PMC: 4175960. View

Avila Bernabeu A, Cavero Escribano T, Cao Vilarino M . Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron. 2020; 144(11):537-549. DOI: 10.1159/000508920. View

Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle A, Ogawa M . Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015; 125(21):3253-62. PMC: 4449039. DOI: 10.1182/blood-2014-09-600411. View

10.

Richards A, Liszewski M, Kavanagh D, Fang C, Moulton E, Fremeaux-Bacchi V . Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2006; 44(1-3):111-22. DOI: 10.1016/j.molimm.2006.07.004. View

11.

Puraswani M, Khandelwal P, Saini H, Saini S, Gurjar B, Sinha A . Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol. 2019; 10:1282. PMC: 6567923. DOI: 10.3389/fimmu.2019.01282. View

12.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M, Ngo S . Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4):554-62. PMC: 3613948. DOI: 10.2215/CJN.04760512. View

13.

Noris M, Remuzzi G . Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013; 22(6):704-12. DOI: 10.1097/MNH.0b013e328365b3fe. View

14.

Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P . Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005; 14(5):703-12. DOI: 10.1093/hmg/ddi066. View

15.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S . Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013; 24(3):475-86. PMC: 3582207. DOI: 10.1681/ASN.2012090884. View

16.

Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang W, le Quintrec M . Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-6. PMC: 3719402. DOI: 10.1038/ng.2590. View

17.

Sellier-Leclerc A, Fremeaux-Bacchi V, Dragon-Durey M, Macher M, Niaudet P, Guest G . Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007; 18(8):2392-400. DOI: 10.1681/ASN.2006080811. View

18.

Hofer J, Janecke A, Zimmerhackl L, Riedl M, Rosales A, Giner T . Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2012; 8(3):407-15. PMC: 3586960. DOI: 10.2215/CJN.01260212. View

19.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M . Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Front Immunol. 2019; 10:853. PMC: 6504697. DOI: 10.3389/fimmu.2019.00853. View

20.

Dragon-Durey M, Loirat C, Cloarec S, Macher M, Blouin J, Nivet H . Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2004; 16(2):555-63. DOI: 10.1681/ASN.2004050380. View